Is Ozempic Helping Women Get Pregnant? Understanding the Link

Last reviewed: July 3, 2026

Last updated: July 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Weight management and metabolic health play significant roles in female fertility, particularly in conditions like polycystic ovary syndrome (PCOS), which affects approximately 1 in 10 women of reproductive age. GLP-1 receptor agonists, including semaglutide, have emerged as tools that may support both weight loss and improved reproductive outcomes by addressing the underlying metabolic dysfunction. This article explores the emerging evidence behind GLP-1 therapy and female reproductive health.

How GLP-1 Medications Impact Reproductive Health in Women

GLP-1 receptor agonists work by improving insulin sensitivity and reducing appetite signaling in the brain, which can help women achieve and maintain a healthy body weight. For women with PCOS or insulin resistance, excess insulin can disrupt hormone production and interfere with ovulation. By lowering insulin levels and promoting gradual, sustainable weight loss, GLP-1 medications may restore more regular menstrual cycles and improve egg quality. Clinical observations suggest that weight loss of just 5-10% can significantly improve fertility markers in women with metabolic dysfunction.

Beyond weight loss alone, semaglutide and similar GLP-1 compounds influence hormonal pathways that directly affect reproduction. These medications increase glucagon-like peptide-1 signaling, which interacts with metabolic networks that regulate estrogen and androgen balance. Women using GLP-1 therapy often report improved hormonal stability, reduced excess hair growth (hirsutism), and clearer skin—common signs that androgens are normalizing. The connection between metabolic control and reproductive hormones explains why many women experience fertility improvements even before reaching their goal weight.

PCOS, Insulin Resistance, and GLP-1 Treatment Outcomes

Polycystic ovary syndrome is characterized by insulin resistance, irregular ovulation, and elevated androgen levels—a trio that often prevents pregnancy. Approximately 70-80% of women with PCOS have underlying insulin resistance, meaning their bodies do not respond normally to the hormone insulin. This chronic hyperinsulinemia triggers the ovaries to produce excess testosterone and other androgens, which suppress ovulation and disrupt follicle development. GLP-1 medications address this root cause by improving how cells respond to insulin, thereby reducing circulating insulin levels and lowering androgen production.

Research on GLP-1 use in PCOS populations shows promising results: improved ovulation rates, better egg quality, and higher rates of successful conception in women who previously struggled with anovulation. One observational study noted that women using GLP-1 therapy experienced restoration of regular menstrual cycles within 3-6 months of treatment initiation. The metabolic improvement appears to reset the hormonal environment in ways that standard birth control or anti-androgen medications alone cannot achieve. For women seeking pregnancy who have PCOS and insulin resistance, GLP-1 therapy represents a targeted approach to treating the underlying metabolic driver of infertility.

Weight Loss and Ovulation: The Evidence Behind the Link

Fertility researchers have long documented that modest weight loss dramatically improves ovulation in women with obesity and irregular cycles. A landmark meta-analysis found that weight reduction of 5-10% resulted in spontaneous ovulation restoration in 55-100% of women with anovulation related to obesity. The mechanism involves improved insulin sensitivity, normalized leptin signaling, and restoration of the luteinizing hormone (LH) pulse necessary for regular ovulation. GLP-1 medications accelerate this process by creating a metabolic state favorable to hormonal balance while helping women lose weight at a sustainable pace.

The timing of weight loss also matters: rapid, severe weight loss can paradoxically impair fertility by triggering adaptive suppression of reproductive hormones. GLP-1 therapy promotes gradual weight loss—typically 1-2 pounds per week—which allows the body's metabolic and reproductive systems to adapt together. Women on semaglutide or tirzepatide report that their energy levels remain stable during weight loss, which supports consistent ovulation and improved egg quality. This measured approach to weight management may explain why GLP-1 users often experience fertility improvements that persist long-term.

Personalized GLP-1 Treatment and Your Fertility Goals

The PlexusDx Precision Peptide Genetic Test analyzes FTO (rs9939609) and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Whether you choose Semaglutide Injection, Oral Semaglutide, Tirzepatide Injection, or PlexusDx's dual-compound GLP-Squared formulation, all medications come from licensed 503A compounding pharmacies and are HSA/FSA eligible. Your dose may adjust based on your body's response, but PlexusDx's pricing model ensures your monthly cost remains flat—your investment in metabolic health and reproductive wellness stays predictable. Working with a PlexusDx provider allows you to integrate fertility goals into your weight management strategy from day one, ensuring every aspect of treatment supports both your metabolic and reproductive health.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Can semaglutide help me get pregnant if I have PCOS?

Yes, semaglutide may support fertility outcomes in PCOS by improving insulin sensitivity and restoring ovulation. Since PCOS-related infertility is primarily driven by insulin resistance and excess androgens, addressing these root causes through GLP-1 therapy can normalize menstrual cycles and improve egg quality. PlexusDx Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan) and works best when combined with lifestyle support and monitoring of reproductive health markers.

How much weight loss do I need to see fertility improvements?

Clinical evidence shows that 5-10% weight loss can restore ovulation and improve fertility in women with weight-related anovulation. Many women report normalized cycles and improved fertility markers within 3-6 months of starting GLP-1 therapy, often before reaching their ultimate weight loss goal. The metabolic improvements from GLP-1 treatment may precede visible weight loss, meaning reproductive benefits can begin early.

Is PlexusDx semaglutide FDA-approved?

PlexusDx semaglutide is compounded by licensed 503A pharmacies; compounded medications are not FDA-approved but are legal and regulated. PlexusDx serves all 50 states without insurance requirements, and all medications are HSA/FSA eligible. Your provider will discuss the compounded formulation and how it fits your fertility and weight management plan.

What are the side effects of GLP-1 therapy, and could they affect pregnancy?

Common GLP-1 side effects include nausea, constipation, and reduced appetite—most mild and temporary. Women planning pregnancy should discuss the timing of conception with their PlexusDx provider, as most recommend establishing metabolic stability before attempting pregnancy. Current evidence suggests GLP-1 therapy improves the hormonal environment for conception, though individual consultation is essential for personalized guidance.

How does the Precision Peptide Genetic Test help with fertility?

The Precision Peptide Genetic Test ($298) analyzes genetic variants in MC4R and FTO, and GIPR that influence insulin sensitivity, weight regulation, and metabolic hormones affecting reproduction. By identifying your unique peptide pathway predispositions, PlexusDx providers can optimize your GLP-1 therapy to maximize both metabolic improvement and fertility outcomes. This personalized approach ensures your treatment aligns with your reproductive goals.

Related Reading

• Lifemd Ozempic
• Eden Ozempic
• Ro Ozempic
• Mochi Ozempic

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.